Nuclide Therapeutics provides radiopharmaceutical medicines that combine nuclear medicine and biotechnology.
Nuclide Therapeutics has raised $6.7M in total funding. The most recent round was Seed. The last funding was announced in September 2025.
Nuclide Therapeutics's investors include Marathon Beteiligungs, Wellcome Trust.
Nuclide Therapeutics is headquartered in London, United Kingdom.
Nuclide Therapeutics provides radiopharmaceutical medicines that combine nuclear medicine and biotechnology.
Nuclide Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nuclide Therapeutics — Funding & Investors." VCBacked, September 22, 2025, https://www.vcbacked.co/company/nuclide-therapeutics. Accessed September 14, 2026.
VCBacked. (2025). Nuclide Therapeutics — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/nuclide-therapeutics
{{cite web |title=Nuclide Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nuclide-therapeutics |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated